or Try an Advanced Search...

    ETF Components for FTXH - First Trust Nasdaq Pharmaceuticals ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    BMY B -0.55 8.89
    JNJ D 0.00 6.95
    PFE F -0.45 6.81
    ABBV F -0.04 6.56
    MRK F -0.13 6.31
    GILD B -0.21 4.43
    CAH B -0.51 4.09
    VTRS A -0.04 3.97
    UTHR C -0.09 3.90
    ZTS D -0.33 3.61
    JAZZ B 1.03 3.45
    AMGN D -0.65 3.37
    LLY F -1.52 3.11
    BIIB F -0.44 3.06
    REGN F 0.06 2.51
    CRL D -0.03 2.47
    OGN F 0.64 2.43
    ELAN D -0.07 1.83
    MEDP F 0.00 1.79
    NBIX C -0.33 1.39
    HALO F -0.35 1.19
    EXEL B 0.42 1.12
    ALKS C 0.38 1.06
    PBH A 0.00 0.98
    PRGO C -0.77 0.97
    CORT B 1.62 0.82
    ACLX C 0.83 0.73
    PTGX D 4.06 0.71
    TGTX B 3.24 0.69
    ALNY D -0.43 0.65
    ITCI B -0.41 0.63
    ADMA B 0.09 0.62
    INCY C -0.05 0.62
    RNA C -0.80 0.60
    AMRX C 0.59 0.55
    VCEL A 0.64 0.54
    ACAD C -3.01 0.54
    BPMC C -0.41 0.53
    VRTX D -0.73 0.51
    KYMR D -1.38 0.50
    ROIV D 1.57 0.50
    INSM C -1.32 0.49
    TWST F -1.54 0.48
    KRYS C -0.12 0.48
    EXAS D -0.47 0.44
    VKTX F -1.06 0.44
    BMRN F -0.90 0.43
    SRPT F -0.43 0.42
    IONS F -0.59 0.41
    MYGN F 1.24 0.29

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Biotechnology Medicine S&P 500 Pharmaceutical Products Cancer Diabetes Life Sciences Infectious Diseases Pain Clinical Development Immunology Inflammation Schizophrenia Animal Health Autoimmune Disease Depressive Disorder Disease Hypertension Nasdaq 100
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Distribution Drug Manufacturers - General

    Recent News for First Trust Nasdaq Pharmaceuticals ETF & its Holdings

    Date Stock Title
    Nov 21 VTRS Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)
    Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
    Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
    Nov 21 TGTX TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
    Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
    Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
    Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
    Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
    Nov 20 ZTS Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)
    Nov 20 MYGN Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
    Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
    Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
    Nov 20 MRK Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
    Nov 20 JNJ Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China
    Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
    Nov 20 MRK Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
    Nov 20 INSM Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
    Nov 20 PFE 5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
    Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
    Nov 20 VKTX Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
    The First Trust Nasdaq Pharmaceuticals ETF is an exchange-traded fund. The investment objective of the Fund is to seek investment results that correspond generally to the price and yield, before the Fund's fees and expenses, of an index called the Nasdaq US Smart Pharmaceuticals Index. The Fund seeks to replicate the holdings and weightings of the Nasdaq US Smart Pharmaceuticals Index so as to generate performance results 95% correlated to that of the Nasdaq US Smart Pharmaceuticals Index.
    Exchange Traded Fund ETF Exchange Traded Funds Stock Market Index Nasdaq 100
    Back to the Main FTXH Page...